A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

NCT04432207 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Portfolio prioritization

Conditions

Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Squamous Non-small-cell Lung Cancer
Large Cell Carcinoma Lung
Adenocarcinoma Lung

Interventions

BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 1
BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 2
BIOLOGICAL: IMU-201 (administered as PD1-Vaxx) - Regimen 3
DRUG: Atezolizumab
DRUG: Standard of care chemotherapy

Sponsor

Imugene Limited